AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million OfferingInvestors Business Daily • 08/14/24
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct OfferingGlobeNewsWire • 08/14/24
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/24
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/24
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/29/24
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: AnalystBenzinga • 07/22/24
Anaptys Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/24
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)GlobeNewsWire • 05/09/24
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli RoyaltiesGlobeNewsWire • 05/09/24
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 05/02/24
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 05/01/24
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to TradeZacks Investment Research • 03/14/24
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/11/24
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual MeetingGlobeNewsWire • 02/29/24
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?Zacks Investment Research • 02/19/24
Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect?Zacks Investment Research • 12/07/23
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsGlobeNewsWire • 11/27/23